Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$85.40

-0.06 (-0.07%)

16:17
04/25/19
04/25
16:17
04/25/19
16:17

BioMarin sees 2019 revenue $1.68B-$1.75B, consensus $1.69B

Sees 2019 non-GAAP income $130M-$170M.

  • 25

    Apr

  • 13

    Jun

BMRN BioMarin
$85.40

-0.06 (-0.07%)

03/04/19
CANT
03/04/19
NO CHANGE
Target $131
CANT
Overweight
BioMarin price target raised to $131 from $126 at Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle raised her price target for BioMarin Pharmaceutical to $131 to reflect Friday's positive Committee for Medicinal Products for Human Use opinion on Palynziq. The analyst thinks the approval is supportive of base business revenue growth, and she models worldwide Palynziq sales of $900M. She keeps an Overweight rating on BioMarin.
04/09/19
RAJA
04/09/19
INITIATION
RAJA
Outperform
BioMarin resumed with an Outperform at Raymond James
Raymond James analyst Reni Benjamin resumed coverage on BioMarin with an Outperform and $110 price target. The analyst said baseline ultra-orphan business is on tract to generate $2.1B by 2024, key read-outs are expected in mid-2019 for its leading Hemophilia A gene therapy asset, and the current pipeline of seven revenue generating products, which could become nine by 2020, are modeled to generate $3.3B in sales by 2024.
04/18/19
PIPR
04/18/19
NO CHANGE
Target $120
PIPR
Overweight
BioMarin bear thesis on Valrox 'does not hold water,' says Piper Jaffray
After hosting a dinner with management, Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on BioMarin with a $120 price target. The bear thesis on the June 6 Valrox Phase 2 year three update readout "simply does not hold water," Raymond tells investors in a research note titled "Everyone Just Take a Breath; Remain Confident in Valrox After Management Dinner." The bear thesis centers around management seeing regular updates to the data, but the company took pains to explain the blinding protocols in place and insist it has been blinded since the two year update, says the analyst. He believes management and remains a buyer of BioMarin shares. Raymond sees the controversy around the data as a "bit of a tempest in a teapot," and he urges investors to "stay the course."
04/18/19
MZHO
04/18/19
NO CHANGE
Target $65
MZHO
Buy
Mizuho defends Wave Life Sciences, says suvodirsen not drisapersen
Mizuho analyst Salim Syed yesterday afternoon came out "defending" shares of Wave Life Sciences (WVE) following the recent selloff. The reaction has been based on false logic, primarily equating Wave Life's suvodirsen to BioMarin's (BMRN) failed drisapersen, Syed told investors in a research note. Suvodirsen "is NOT" drisapersen and the lower suvodirsen Phase 2/3 dosing versus drisapersen's "does not necessarily imply a lesser or even similar dystrophin expression," Syed wrote. Further, the Phase 2/3 dosing "was selected rationally, seems within the therapeutic window, and is likely favorable to current standard of care," he contends. The analyst adds that the Phase 1 safety data "was still generally clean." Syed keeps a Buy rating on Wave Life Sciences with a $65 price target.

TODAY'S FREE FLY STORIES

PGSVY

PGS ASA

$0.00

(0.00%)

05:33
06/20/19
06/20
05:33
06/20/19
05:33
Downgrade
PGS ASA rating change  »

PGS ASA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$20.96

0.08 (0.38%)

05:32
06/20/19
06/20
05:32
06/20/19
05:32
Initiation
Pinduoduo initiated  »

Pinduoduo initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$148.73

1.37 (0.93%)

05:30
06/20/19
06/20
05:30
06/20/19
05:30
Downgrade
Chubb rating change  »

Chubb downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

OPHLY

Ono Pharmaceutical

$0.00

(0.00%)

05:29
06/20/19
06/20
05:29
06/20/19
05:29
Downgrade
Ono Pharmaceutical rating change  »

Ono Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YARIY

Yara

$0.00

(0.00%)

05:27
06/20/19
06/20
05:27
06/20/19
05:27
Downgrade
Yara rating change  »

Yara downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZURVY

Zurich Insurance

$0.00

(0.00%)

05:26
06/20/19
06/20
05:26
06/20/19
05:26
Upgrade
Zurich Insurance rating change  »

Zurich Insurance upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRE

Bank of Ireland

$0.00

(0.00%)

05:24
06/20/19
06/20
05:24
06/20/19
05:24
Upgrade
Bank of Ireland rating change  »

Bank of Ireland upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOC

Physicians Realty Trust

$18.27

0.095 (0.52%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Physicians Realty Trust initiated  »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTA

Healthcare Trust

$29.18

0.16 (0.55%)

05:23
06/20/19
06/20
05:23
06/20/19
05:23
Initiation
Healthcare Trust initiated  »

Healthcare Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HR

Healthcare Realty Trust

$33.14

0.26 (0.79%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Initiation
Healthcare Realty Trust initiated  »

Healthcare Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

SCRYY

Scor

$0.00

(0.00%)

05:22
06/20/19
06/20
05:22
06/20/19
05:22
Upgrade
Scor rating change  »

Scor upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

$39.49

1.175 (3.07%)

05:20
06/20/19
06/20
05:20
06/20/19
05:20
Upgrade
Fresenius Medical rating change  »

Fresenius Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$20.63

0.1 (0.49%)

05:16
06/20/19
06/20
05:16
06/20/19
05:16
Initiation
HP Inc. initiated  »

Deutsche Bank starts HP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

DELL

Dell Technologies

$53.39

1.88 (3.65%)

05:15
06/20/19
06/20
05:15
06/20/19
05:15
Initiation
Dell Technologies initiated  »

Deutsche Bank starts Dell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

FNMA

Fannie Mae

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Fannie Mae initiated  »

Fannie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMCC

Freddie Mac

$0.00

(0.00%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Freddie Mac initiated  »

Freddie Mac initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

05:12
06/20/19
06/20
05:12
06/20/19
05:12
Initiation
Apple initiated  »

Deutsche Bank, fearing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$19.05

-0.21 (-1.09%)

05:07
06/20/19
06/20
05:07
06/20/19
05:07
Recommendations
JetBlue analyst commentary  »

JetBlue price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

, SNY

Sanofi

$44.11

0.99 (2.30%)

05:05
06/20/19
06/20
05:05
06/20/19
05:05
Recommendations
Voyager Therapeutics, Sanofi, Neurocrine analyst commentary  »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$27.87

0.05 (0.18%)

SNY

Sanofi

$44.11

0.99 (2.30%)

NBIX

Neurocrine

$85.47

-0.28 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

ORCL

Oracle

$52.69

-0.19 (-0.36%)

05:02
06/20/19
06/20
05:02
06/20/19
05:02
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BFAM

Bright Horizons

$141.18

1.73 (1.24%)

04:59
06/20/19
06/20
04:59
06/20/19
04:59
Upgrade
Bright Horizons rating change  »

Bright Horizons upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

04:56
06/20/19
06/20
04:56
06/20/19
04:56
Initiation
Enable Midstream initiated  »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHDX

Genomic Health

$54.26

-0.04 (-0.07%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Upgrade
Genomic Health rating change  »

Genomic Health upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

SMG

Scotts Miracle-Gro

$98.53

0.4 (0.41%)

04:55
06/20/19
06/20
04:55
06/20/19
04:55
Conference/Events
Scotts Miracle-Gro management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

04:55
06/20/19
06/20
04:55
06/20/19
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 6/15 Jobless…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.